McDermott Represents Vanda Pharmaceuticals Inc. on Acquisition of PONVORY® | McDermott

McDermott Will & Schulte, a global law firm

DEAL ANNOUNCEMENT / PRESS RELEASE

McDermott Represents Vanda Pharmaceuticals Inc. on Acquisition of PONVORY®

December 13, 2023

Read time: 2 min

International law firm McDermott Will & Emery represented Vanda Pharmaceuticals Inc. (Vanda), a leading global biopharmaceutical company, in its acquisition of US and Canadian rights to PONVORY®, a treatment for adults with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.  

The McDermott deal team was led by Kristian Werling with support from Paul Hughes, Nate Wolfe, Tom Conaghan, Caroline Ngo, Daniel McGuire, Dave Santangelo, Matt Celano, Alex Ruiz, Yuxin Jin, Dan Marino, Margaret Sampson, Anisa Mohanty, Scott Weinstein and Dana McSherry. 

Read Vanda’s announcement here. 

Paul W. Hughes

Socio

Washington, DC

Nathaniel Wolfe

Socio

Nashville, New York – One Vanderbilt Avenue

Thomas P. Conaghan

Socio

Washington, DC, New York – One Vanderbilt Avenue

Caroline H. Ngo

Socio

Washington, DC

David M. Santangelo

Socio

New York – One Vanderbilt Avenue

Alejandro Ruiz

Socio

San Francisco

Yuxin Jin

Associato

New York – One Vanderbilt Avenue

You may also like